Overexpression of the PSAT1 gene in nasopharyngeal carcinoma is an indicator of poor prognosis

Kuang Ming Liao, Tung Bo Chao, Yu Feng Tian, Ching Yih Lin, Sung Wei Lee, Hua Ying Chuang, Ti Chun Chan, Tzu Ju Chen, Chung Hsi Hsing, Ming Jen Sheu, Chien Feng Li

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: Nasopharyngeal carcinoma (NPC) is a common cancer in southern China and Southeast Asia, but risk stratification and treatment outcome in NPC patients remain suboptimal. Our study identified and validated metabolic drivers that are relevant to the pathogenesis of NPC using a published transcriptome. Phosphoserine aminotransferase 1 (PSAT1) is an enzyme that is involved in serine biosynthesis, and its overexpression is associated with colon cancer, non-small cell lung cancer and breast cancer. However, its expression has not been systemically evaluated in patients with NPC. Materials and Methods: We evaluated two public transcriptomes of NPC tissues and benign nasopharyngeal mucosal epithelial tissues that deposited in the NIH Gene Expression Omnibus database under accession number GSE34574 and GSE12452. We also performed immunohistochemical staining and assessment of PSAT1 in a total of 124 NPC patients received radiotherapy and were regularly followed-up until death or loss. The endpoints analyzed were local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-specific survival (DSS), and overall survival (OS). Results: We retrospectively evaluated 124 patients with NPC and found that high PSAT1 expression was associated with poor prognosis of NPC and indicator of advanced tumor stage. High PSAT1 expression also correlated with an aggressive clinical course, with significantly shorter DSS (HR= 2.856, 95% CI 1.599 to 5.101), DMFS (HR= 3.305, 95% CI 1.720 to 6.347), LRFS (HR= 2.834, 95% CI 1.376 to 5.835), and OS HR= 2.935, 95% CI 1.646-5.234) in multivariate analyses. Conclusions: Our study showed that PSAT1 is a potential prognostic biomarker and higher expression of PSAT1 is associated with a poor prognosis in NPC.

Original languageEnglish
Pages (from-to)1088-1094
Number of pages7
JournalJournal of Cancer
Volume7
Issue number9
DOIs
Publication statusPublished - 2016
Externally publishedYes

Fingerprint

phosphoserine aminotransferase
Survival
Genes
Transcriptome
Breast Neoplasms
Neoplasm Metastasis
Nasopharyngeal carcinoma
Recurrence
Southeastern Asia

Keywords

  • Nasopharyngeal carcinoma
  • Prognosis
  • PSAT1

ASJC Scopus subject areas

  • Oncology

Cite this

Liao, K. M., Chao, T. B., Tian, Y. F., Lin, C. Y., Lee, S. W., Chuang, H. Y., ... Li, C. F. (2016). Overexpression of the PSAT1 gene in nasopharyngeal carcinoma is an indicator of poor prognosis. Journal of Cancer, 7(9), 1088-1094. https://doi.org/10.7150/jca.15258

Overexpression of the PSAT1 gene in nasopharyngeal carcinoma is an indicator of poor prognosis. / Liao, Kuang Ming; Chao, Tung Bo; Tian, Yu Feng; Lin, Ching Yih; Lee, Sung Wei; Chuang, Hua Ying; Chan, Ti Chun; Chen, Tzu Ju; Hsing, Chung Hsi; Sheu, Ming Jen; Li, Chien Feng.

In: Journal of Cancer, Vol. 7, No. 9, 2016, p. 1088-1094.

Research output: Contribution to journalArticle

Liao, KM, Chao, TB, Tian, YF, Lin, CY, Lee, SW, Chuang, HY, Chan, TC, Chen, TJ, Hsing, CH, Sheu, MJ & Li, CF 2016, 'Overexpression of the PSAT1 gene in nasopharyngeal carcinoma is an indicator of poor prognosis', Journal of Cancer, vol. 7, no. 9, pp. 1088-1094. https://doi.org/10.7150/jca.15258
Liao, Kuang Ming ; Chao, Tung Bo ; Tian, Yu Feng ; Lin, Ching Yih ; Lee, Sung Wei ; Chuang, Hua Ying ; Chan, Ti Chun ; Chen, Tzu Ju ; Hsing, Chung Hsi ; Sheu, Ming Jen ; Li, Chien Feng. / Overexpression of the PSAT1 gene in nasopharyngeal carcinoma is an indicator of poor prognosis. In: Journal of Cancer. 2016 ; Vol. 7, No. 9. pp. 1088-1094.
@article{24ac85f261e54781962cba4469fa9fe7,
title = "Overexpression of the PSAT1 gene in nasopharyngeal carcinoma is an indicator of poor prognosis",
abstract = "Purpose: Nasopharyngeal carcinoma (NPC) is a common cancer in southern China and Southeast Asia, but risk stratification and treatment outcome in NPC patients remain suboptimal. Our study identified and validated metabolic drivers that are relevant to the pathogenesis of NPC using a published transcriptome. Phosphoserine aminotransferase 1 (PSAT1) is an enzyme that is involved in serine biosynthesis, and its overexpression is associated with colon cancer, non-small cell lung cancer and breast cancer. However, its expression has not been systemically evaluated in patients with NPC. Materials and Methods: We evaluated two public transcriptomes of NPC tissues and benign nasopharyngeal mucosal epithelial tissues that deposited in the NIH Gene Expression Omnibus database under accession number GSE34574 and GSE12452. We also performed immunohistochemical staining and assessment of PSAT1 in a total of 124 NPC patients received radiotherapy and were regularly followed-up until death or loss. The endpoints analyzed were local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-specific survival (DSS), and overall survival (OS). Results: We retrospectively evaluated 124 patients with NPC and found that high PSAT1 expression was associated with poor prognosis of NPC and indicator of advanced tumor stage. High PSAT1 expression also correlated with an aggressive clinical course, with significantly shorter DSS (HR= 2.856, 95{\%} CI 1.599 to 5.101), DMFS (HR= 3.305, 95{\%} CI 1.720 to 6.347), LRFS (HR= 2.834, 95{\%} CI 1.376 to 5.835), and OS HR= 2.935, 95{\%} CI 1.646-5.234) in multivariate analyses. Conclusions: Our study showed that PSAT1 is a potential prognostic biomarker and higher expression of PSAT1 is associated with a poor prognosis in NPC.",
keywords = "Nasopharyngeal carcinoma, Prognosis, PSAT1",
author = "Liao, {Kuang Ming} and Chao, {Tung Bo} and Tian, {Yu Feng} and Lin, {Ching Yih} and Lee, {Sung Wei} and Chuang, {Hua Ying} and Chan, {Ti Chun} and Chen, {Tzu Ju} and Hsing, {Chung Hsi} and Sheu, {Ming Jen} and Li, {Chien Feng}",
year = "2016",
doi = "10.7150/jca.15258",
language = "English",
volume = "7",
pages = "1088--1094",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "9",

}

TY - JOUR

T1 - Overexpression of the PSAT1 gene in nasopharyngeal carcinoma is an indicator of poor prognosis

AU - Liao, Kuang Ming

AU - Chao, Tung Bo

AU - Tian, Yu Feng

AU - Lin, Ching Yih

AU - Lee, Sung Wei

AU - Chuang, Hua Ying

AU - Chan, Ti Chun

AU - Chen, Tzu Ju

AU - Hsing, Chung Hsi

AU - Sheu, Ming Jen

AU - Li, Chien Feng

PY - 2016

Y1 - 2016

N2 - Purpose: Nasopharyngeal carcinoma (NPC) is a common cancer in southern China and Southeast Asia, but risk stratification and treatment outcome in NPC patients remain suboptimal. Our study identified and validated metabolic drivers that are relevant to the pathogenesis of NPC using a published transcriptome. Phosphoserine aminotransferase 1 (PSAT1) is an enzyme that is involved in serine biosynthesis, and its overexpression is associated with colon cancer, non-small cell lung cancer and breast cancer. However, its expression has not been systemically evaluated in patients with NPC. Materials and Methods: We evaluated two public transcriptomes of NPC tissues and benign nasopharyngeal mucosal epithelial tissues that deposited in the NIH Gene Expression Omnibus database under accession number GSE34574 and GSE12452. We also performed immunohistochemical staining and assessment of PSAT1 in a total of 124 NPC patients received radiotherapy and were regularly followed-up until death or loss. The endpoints analyzed were local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-specific survival (DSS), and overall survival (OS). Results: We retrospectively evaluated 124 patients with NPC and found that high PSAT1 expression was associated with poor prognosis of NPC and indicator of advanced tumor stage. High PSAT1 expression also correlated with an aggressive clinical course, with significantly shorter DSS (HR= 2.856, 95% CI 1.599 to 5.101), DMFS (HR= 3.305, 95% CI 1.720 to 6.347), LRFS (HR= 2.834, 95% CI 1.376 to 5.835), and OS HR= 2.935, 95% CI 1.646-5.234) in multivariate analyses. Conclusions: Our study showed that PSAT1 is a potential prognostic biomarker and higher expression of PSAT1 is associated with a poor prognosis in NPC.

AB - Purpose: Nasopharyngeal carcinoma (NPC) is a common cancer in southern China and Southeast Asia, but risk stratification and treatment outcome in NPC patients remain suboptimal. Our study identified and validated metabolic drivers that are relevant to the pathogenesis of NPC using a published transcriptome. Phosphoserine aminotransferase 1 (PSAT1) is an enzyme that is involved in serine biosynthesis, and its overexpression is associated with colon cancer, non-small cell lung cancer and breast cancer. However, its expression has not been systemically evaluated in patients with NPC. Materials and Methods: We evaluated two public transcriptomes of NPC tissues and benign nasopharyngeal mucosal epithelial tissues that deposited in the NIH Gene Expression Omnibus database under accession number GSE34574 and GSE12452. We also performed immunohistochemical staining and assessment of PSAT1 in a total of 124 NPC patients received radiotherapy and were regularly followed-up until death or loss. The endpoints analyzed were local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-specific survival (DSS), and overall survival (OS). Results: We retrospectively evaluated 124 patients with NPC and found that high PSAT1 expression was associated with poor prognosis of NPC and indicator of advanced tumor stage. High PSAT1 expression also correlated with an aggressive clinical course, with significantly shorter DSS (HR= 2.856, 95% CI 1.599 to 5.101), DMFS (HR= 3.305, 95% CI 1.720 to 6.347), LRFS (HR= 2.834, 95% CI 1.376 to 5.835), and OS HR= 2.935, 95% CI 1.646-5.234) in multivariate analyses. Conclusions: Our study showed that PSAT1 is a potential prognostic biomarker and higher expression of PSAT1 is associated with a poor prognosis in NPC.

KW - Nasopharyngeal carcinoma

KW - Prognosis

KW - PSAT1

UR - http://www.scopus.com/inward/record.url?scp=84990247616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990247616&partnerID=8YFLogxK

U2 - 10.7150/jca.15258

DO - 10.7150/jca.15258

M3 - Article

AN - SCOPUS:84990247616

VL - 7

SP - 1088

EP - 1094

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 9

ER -